Immunotherapy and Coronavirus Disease 2019: Challenges and Possibilities.
作者信息
Bakhribah Hatoon, Alfayea Turki
机构信息
Medical Oncology Department, King Fahad Medical City, Riyadh, Saudi Arabia.
Medical Oncology Department, King Abdulaziz Medical City, Jeddah, Saudi Arabia.
出版信息
J Thorac Oncol. 2020 Nov;15(11):1709-1710. doi: 10.1016/j.jtho.2020.08.015. Epub 2020 Oct 23.
Abstract
摘要
相似文献
1
Immunotherapy and Coronavirus Disease 2019: Challenges and Possibilities.免疫疗法与2019冠状病毒病：挑战与机遇
J Thorac Oncol. 2020 Nov;15(11):1709-1710. doi: 10.1016/j.jtho.2020.08.015. Epub 2020 Oct 23.
2
Pathology of 2019 Novel Coronavirus Pneumonia: A Dynamic Disease Process.2019新型冠状病毒肺炎病理学：一个动态的疾病过程
J Thorac Oncol. 2020 May;15(5):e67-e68. doi: 10.1016/j.jtho.2020.03.015.
3
Pulmonary Pathology of Early Phase 2019 Novel Coronavirus Pneumonia.2019新型冠状病毒肺炎早期阶段的肺部病理学
J Thorac Oncol. 2020 May;15(5):e67. doi: 10.1016/j.jtho.2020.03.013.
4
Convalescent Plasma to Treat COVID-19: Possibilities and Challenges.康复血浆治疗新冠病毒病：可能性与挑战
JAMA. 2020 Apr 28;323(16):1561-1562. doi: 10.1001/jama.2020.4940.
5
Lung Cancer Surgical Management During the Outbreak of Coronavirus Disease 2019.2019年冠状病毒病疫情期间的肺癌外科治疗
J Thorac Oncol. 2020 Jun;15(6):e81. doi: 10.1016/j.jtho.2020.03.027. Epub 2020 Apr 11.
6
Coronavirus Disease 2019 (COVID-19): Emerging and Future Challenges for Dental and Oral Medicine.2019冠状病毒病（COVID-19）：口腔医学面临的新出现和未来挑战
J Dent Res. 2020 Aug;99(9):1113. doi: 10.1177/0022034520932149. Epub 2020 May 28.
7
The novel coronavirus (SARS-CoV-2) infections in China: prevention, control and challenges.中国的新型冠状病毒（严重急性呼吸综合征冠状病毒2）感染：预防、控制与挑战
Intensive Care Med. 2020 Apr;46(4):591-593. doi: 10.1007/s00134-020-05977-9. Epub 2020 Mar 2.
8
COVID-19: Crisis Management in Lung Cancer Surgery.新型冠状病毒肺炎：肺癌手术中的危机管理
Rev Port Cir Cardiotorac Vasc. 2020 Apr-Jun;27(2):75.
9
[DZK Recommendations for Tuberculosis, BCG and COVID-19 in Germany - (Official Abbreviation of Coronavirus Disease 2019 Caused by the New Coronavirus SARS-CoV-2)].[德国关于结核病、卡介苗和新型冠状病毒肺炎（严重急性呼吸综合征冠状病毒2型引起的2019冠状病毒病的官方缩写）的建议]
Pneumologie. 2020 Jul;74(7):412-416. doi: 10.1055/a-1199-6721. Epub 2020 Jul 16.
10
[Analysis of coronavirus disease-19 (COVID-19) based on SARS autopsy].基于严重急性呼吸综合征（SARS）尸检的新型冠状病毒肺炎（COVID-19）分析
Zhonghua Bing Li Xue Za Zhi. 2020 Apr 8;49(4):291-293. doi: 10.3760/cma.j.cn112151-20200211-00114.
引用本文的文献
1
International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials.国际肺癌研究协会研究 2019 年冠状病毒病对国际肺癌临床试验的影响。
J Thorac Oncol. 2022 May;17(5):651-660. doi: 10.1016/j.jtho.2022.01.017. Epub 2022 Feb 17.
本文引用的文献
1
Atypical Skin Manifestations During Immune Checkpoint Blockage in Coronavirus Disease 2019-Infected Patients With Lung Cancer.COVID-19 感染肺癌患者接受免疫检查点阻断治疗期间出现非典型皮肤表现。
J Thorac Oncol. 2020 Nov;15(11):1767-1772. doi: 10.1016/j.jtho.2020.06.019. Epub 2020 Jul 9.
2
Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases.COVID-19 皮肤表现分类：西班牙 375 例快速前瞻性全国共识研究。
Br J Dermatol. 2020 Jul;183(1):71-77. doi: 10.1111/bjd.19163. Epub 2020 Jun 10.
3
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives.非小细胞肺癌的免疫治疗：现状与未来展望
Immune Netw. 2020 Jan 27;20(1):e10. doi: 10.4110/in.2020.20.e10. eCollection 2020 Feb.
4
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.纳武利尤单抗联合伊匹单抗治疗晚期非小细胞肺癌。
N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.
5
Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.靶向治疗和免疫治疗的皮肤、口腔黏膜、头发和指甲毒性副作用。
Am J Clin Dermatol. 2018 Nov;19(Suppl 1):31-39. doi: 10.1007/s40257-018-0384-3.
6
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.免疫检查点抑制剂治疗患者免疫相关不良反应的管理：美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.
7
Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.比较 PD-1 与 PD-L1 抑制剂在非小细胞肺癌中的毒性特征：文献系统分析。
Cancer. 2018 Jan 15;124(2):271-277. doi: 10.1002/cncr.31043. Epub 2017 Sep 28.
8
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.抗PD-1/PD-L1免疫检查点抗体的皮肤并发症
Curr Opin Oncol. 2016 Jul;28(4):254-63. doi: 10.1097/CCO.0000000000000290.
9
Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy.接受抗PD-L1和抗PD-1治疗患者苔藓样反应的免疫组织化学分析
J Cutan Pathol. 2016 Apr;43(4):339-46. doi: 10.1111/cup.12666. Epub 2016 Feb 10.
10
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.纳武利尤单抗用于可切除和不可切除转移性黑色素瘤：免疫相关不良事件的特征及其与预后的关联
Clin Cancer Res. 2016 Feb 15;22(4):886-94. doi: 10.1158/1078-0432.CCR-15-1136. Epub 2015 Oct 7.
Zotero 插件